• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
  • Our Technology

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states with the favorable drug-like qualities of traditional small molecules.
  • Clinical Trials

    Get the latest information about our ongoing clinical trials.
    Details
  • Latest News

      • JULY 31, 2017

      Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results

      Reports multiple recent developments and milestones

      Plans to report top-line results from the second monotherapy dosing cohort of the ACHIEVE global Phase 2 clinical trial of SB 9200 in chronic HBV in 4Q 2017
      Successful $40 million equity financing expected to fund company through end of 2019
      HOPKINTON, Mass., July 31, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced second quarter 2017 financial results and provided an update on recent corporate and clinical developments.
      “We are pleased wit…

      Read more
      • JULY 10, 2017

      Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®

      HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank’s oral selective immunomodulator, SB 9200, co-administered with Gilead’s Vemlidy® (tenofovir alafenamide) in chronic Hepatitis B (HBV) patients.
      “We are excited to be starting a new Phase 2 trial, which will be funded and implemented by Gilead Sciences and has the potential to accelerate the development p…

      Read more